2003
Acquisition of Wallace Laboratories in U.K
In license of a glucosamine product for Merck, Kga
2004
Divestment of two cardiovascular products from UCB
Joint venture between Bristol and Grupo Ferrer
In license of a osteoporosis product for Rovi pharmaceuticals
2005
Out license of the first biotech products in Spain (Oryzon Genomics)
Out license of exxenterol (lipid lowering drug)
2006
Agreement with the Technology park of Madrid
Agreement with Scientific park of Barcelona
2007
Acquisition of the company Pharmaut in Portugal
Divestment of the cardiovascular portfolio of P&G in Europe
2008
Contract manufacturing agreement with Farmalider (25% MS of ibuprofen in Spain)
Entrance in the Board of PULEVA Biotech
In license of an OTC portfolio for BOEHRINGER INGELHEIM
2009
European Business Development contract with P&G
Acquisition of 7 pharma products for SINTEX
Acquisition of 25% of the export company Pharmaphenix
Out license of three products of CHEMO Group for the UK market
2010
European Business Development agreement with SANOFI
European Business Development Agreement with WARNER CHILCOTT
Business development agreement with ADAMED
2011
New Project in WHC with BOEHRINGER
In license of 6 OTC products EXTREFARMA
ISDIN introduction work in Nordic Countries
Foundation of PLASMIA BIOTECH
New Agreement with Boehringer Ingelheim (OTC)
2012
European agreement with TILLOTTS PHARMA
Launch of BRILL PHARMA in Spain
BD Agreement with RECORDATI
2013
Foundation of PROKREA
ISDIN introduction in South Africa
Agreement with MDI Australia for respiratory products
Out license of a prescription dermatological product to IFC Cantabria
2014
In license of ectoin® franchise for Spain from BITOP
Foundation of PROKREA
2015
Out license of a respiratory product for BOEHRINGER INGELHEIM
In license of ILUVIEN® from ALIMERA SCIENCES INC USA
Divestment of a Dermatology portfolio (three products) to IFC CANTABRIA
Out license of ORL portfolio (4 products) to IFC Cantabria
Joint Venture with URSAPHARM AG in Portugal
2016
In license of an ophthalmic portfolio for BRILL PHARMA
In license of Openvista for Spain
INDUSTRY EXPERTISE
Pharmaceuticals
Consumer Care
Drug Delivery
Biomedical Devices
Biotechnology
CONSULTING SERVICES
Market Assessment
IN License
OUT License
Merger/Acquisition
Opportunity Assessment
MORE INFO
www.medifuture.es
INDUSTRY EXPERTISE
Pharmaceuticals
Consumer Care
Drug Delivery
Biomedical Devices
Biotechnology
CONSULTING SERVICES
Market Assessment
IN License
OUT License
Merger/Acquisition
Opportunity Assessment
MORE INFO
www.medifuture.es